Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis.

about

Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis.

Item

http://www.wikidata.org/entity/Q47404960

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Emerging therapeutic targets c ...... tment of systemic amyloidosis.

@en

Emerging therapeutic targets c ...... tment of systemic amyloidosis.

@nl

type

Item

label

Emerging therapeutic targets c ...... tment of systemic amyloidosis.

@en

Emerging therapeutic targets c ...... tment of systemic amyloidosis.

@nl

prefLabel

Emerging therapeutic targets c ...... tment of systemic amyloidosis.

@en

Emerging therapeutic targets c ...... tment of systemic amyloidosis.

@nl

P1476

Emerging therapeutic targets c ...... tment of systemic amyloidosis.

@en

P2093

Giampaolo Merlini

http://www.w3.org/2001/XMLSchema#string

Mario Nuvolone

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE)

Fibril in senile systemic amyloidosis is derived from normal transthyretin

Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models

Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization

Trapping of palindromic ligands within native transthyretin prevents amyloid formation

Potent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte Proteotoxicity

AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin

Evolving landscape in the management of transthyretin amyloidosis

Therapeutic genome editing: prospects and challenges

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

P304

1095-1110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14728222.2017.1398235

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29076382

http://www.w3.org/2001/XMLSchema#string